Karyopharm reports Q1 revenue up 17% as endometrial cancer study completes

May 14, 2026 7:30 AM

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) reported first quarter 2026 total revenue of $35.1 million, compared to $30.0 million in the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found